Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 InfluenzaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This cross-sectional study asked whether the gut microbiota of COVID-19 patients differs from that of H1N1 influenza patients and healthy people. Researchers compared fecal bacterial communities across the three groups to look for a disease-specific microbial signature. Gut microbiota were characterized by 16S ribosomal RNA gene V3-V4 region sequencing of stool samples. The team then tested whether selected bacteria could serve as biomarkers to tell the groups apart. Diagnostic accuracy was summarized using the area under the receiver operating characteristic curve, reported as an AUC value.
Who was studied?
The study included 30 patients with COVID-19, 24 patients with influenza A (H1N1), and 30 matched healthy controls. All were human participants, and the comparison focused on differences in the intestinal microbiota by disease group. COVID-19 is caused by SARS-CoV-2, and the study was motivated by frequent gastrointestinal symptoms and detection of viral RNA in stool. The design was cross-sectional, sampling each participant at a single time point rather than following them over time.
What were the most important findings?
Compared with healthy controls, COVID-19 patients had significantly reduced bacterial diversity. They showed a higher relative abundance of opportunistic pathogens including Streptococcus, Rothia, Veillonella, and Actinomyces, and fewer beneficial symbionts. Five bacterial biomarkers distinguished COVID-19 patients from healthy controls with an AUC up to 0.89. Patients with H1N1 influenza showed lower diversity and a different overall microbial composition than COVID-19 patients. Seven biomarkers separated the COVID-19 and H1N1 cohorts with an AUC of 0.94, indicating the two infections carry distinct gut signatures.
What are the greatest implications of this study?
The results suggest the gut microbial signature of COVID-19 is distinct from both influenza and health, pointing to possible use of gut bacteria as a diagnostic aid or therapeutic target. The high AUC values indicate the signatures separated groups well in this sample. Because the study is cross-sectional and small, it cannot show whether dysbiosis causes disease or results from it. The authors state that further validation is needed before clinical application. The distinct COVID-19 and H1N1 signatures raise the possibility that different respiratory infections leave different marks on the gut.